{"protocolSection": {"identificationModule": {"nctId": "NCT02091362", "orgStudyIdInfo": {"id": "15261"}, "secondaryIdInfos": [{"id": "I1R-MC-GLDI", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2013-003834-33", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus", "officialTitle": "The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-03"}, "primaryCompletionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-03-18", "studyFirstSubmitQcDate": "2014-03-18", "studyFirstPostDateStruct": {"date": "2014-03-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-06-06", "resultsFirstSubmitQcDate": "2018-07-17", "resultsFirstPostDateStruct": {"date": "2018-07-19", "type": "ACTUAL"}, "dispFirstSubmitDate": "2015-05-08", "dispFirstSubmitQcDate": "2015-05-08", "dispFirstPostDateStruct": {"date": "2015-05-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-07-17", "lastUpdatePostDateStruct": {"date": "2018-07-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The main purpose of the trial is to determine the effect of a study drug known as LY2409021 on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when compared to placebo. The study has two periods. Each participant will receive LY2409021 or placebo in each period. At least 4 weeks will pass between periods. The study will last about 23 weeks for each participant. Participants may remain on stable dose metformin, as prescribed by their personal physician."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 270, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.", "interventionNames": ["Drug: Placebo", "Drug: Metformin"]}, {"label": "LY2409021", "type": "EXPERIMENTAL", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.", "interventionNames": ["Drug: LY2409021", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "LY2409021", "description": "Administered orally", "armGroupLabels": ["LY2409021"]}, {"type": "DRUG", "name": "Placebo", "description": "Administered orally", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Administered as background therapy.", "armGroupLabels": ["LY2409021", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure", "description": "Systolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM).", "timeFrame": "Baseline, 6 Weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline to 6 Weeks in Mean 24-Hour Diastolic Blood Pressure", "description": "Diastolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "timeFrame": "Baseline, 6 Weeks"}, {"measure": "Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Peripheral Pulse Rate", "description": "Pulse rate obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "timeFrame": "Baseline, 6 Weeks"}, {"measure": "Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Pulse Pressures", "description": "Pulse Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "timeFrame": "Baseline, 6 Weeks"}, {"measure": "Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Mean Arterial Pressures (MAP)", "description": "Mean Arterial Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "timeFrame": "Baseline, 6 Weeks"}, {"measure": "Change From Baseline in Hemoglobin A1c (HbA1c)", "description": "LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "timeFrame": "Baseline, 6 Weeks"}, {"measure": "Population Pharmacokinetics: Apparent Clearance of LY2409021", "description": "Population pharmacokinetic parameter apparent clearance (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time and was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.", "timeFrame": "Days 7, 21, 42, 70, 77, 91, 112, 140; 15 minute Predose and Days 7 and 77: 1 hour Postdose."}, {"measure": "Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021", "description": "Population pharmacokinetic parameter, apparent volume of distribution (V/F) is a theoretical volume that a drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Apparent volume of distribution (V/F) was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.", "timeFrame": "Days 7, 21, 42, 70, 77, 91, 112, 140; Predose and Days 7 and 77: 1 hour Postdose."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have type 2 diabetes mellitus (according to the World Health Organization diagnostic criteria) and use diet and exercise alone or in combination with a stable dose of metformin ( \\>/=1000 mg/day \\[or \\<1000 mg, if documented intolerance to 1000 mg or higher dosages\\] immediate-release metformin or extended-release metformin for at least 2 months before screening).\n* Have glycated hemoglobin (HbA1c) values \\>/=6.5% and \\</=8.5%, as determined by the central laboratory at screening.\n* Have mean blood pressures \\>90/60 millimeters of mercury (mm Hg) and \\<140/90 mm Hg at screening.\n* If being treated for hypertension, are taking 3 or fewer antihypertensive medications and have been taking stable doses of the same medications for at least 1 month before screening.\n* Stable body weights (\u00b15%) for \\>/=3 months before screening.\n* Body mass indexes \\>/=20 kilograms/meters squared (kg/m\u00b2) and \\<40 kg/m\u00b2.\n* In the investigator's opinion, are well motivated, capable, and willing to:\n\n  * Reliably administer the oral study drug once daily;\n  * Maintain a study diary;\n  * Perform self-monitored blood glucose testing; and\n  * Wear an ambulatory blood pressure monitoring device for at least 24 hours (on multiple occasions).\n* Are women not of child-bearing potential due to:\n\n  * Surgical sterilization, hysterectomy, or bilateral oophorectomy (at least 6 weeks postsurgery) or tubal ligation (confirmed by medical history); or\n  * Menopause. Women with an intact uterus are deemed menopausal if they have a cessation of menses for at least 1 year with follicle stimulating hormone \\>40 milli-international units per milliliter (mIU/mL), are not taking hormones or oral contraceptives within 1 year, and are otherwise healthy.\n* Males who are sexually active and/or have partners of child-bearing age must use reliable methods of birth control during the study and until 3 months after the last doses of study medication. These requirements do not apply if a participant or his partner has been surgically sterilized or is not between menarche and 1 year postmenopausal.\n\nExclusion Criteria:\n\n* Have severe gastrointestinal disease that may significantly affect gastric emptying or motility.\n* Previous histories or active diagnoses of pancreatitis.\n* Acute or chronic hepatitis, signs or symptoms of any other liver disease, or alanine aminotransferase (ALT) level greater than 2.5 times the upper limit of normal (ULN).\n* Elevated total bilirubin (greater than 2 times ULN), clinically suspicious signs or symptoms of cirrhosis or history of cirrhosis.\n* Mean resting pulse rate (PR) less than 60 beats per minute (bpm) or greater than 100 bpm.\n* Current diagnosis or personal history of neuroendocrine tumors, family history of any type of multiple endocrine neoplasia, or Von Hippel-Lindau disease.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Advanced Clinical Research Institute", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "National Research Institute", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Artemis Institute for Clinical Research", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Orange County Research Center", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "University Clinical Investigators, Inc.", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Berma Research", "city": "Fort Lauderdale", "state": "Florida", "zip": "33316", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "East Coast Clinical Research", "city": "Jacksonville", "state": "Florida", "zip": "32204", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Suncoast Research Group, LLC", "city": "Miami", "state": "Florida", "zip": "33135", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Cedar-Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Midwest Institute for Clinical Research", "city": "Indianapolis", "state": "Indiana", "zip": "46260", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "L-Marc Research Center", "city": "Louisville", "state": "Kentucky", "zip": "40213", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Maine Research Associates", "city": "Auburn", "state": "Maine", "zip": "04210", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"facility": "Alzohaili Medical Consultants", "city": "Dearborn", "state": "Michigan", "zip": "48124", "country": "United States", "geoPoint": {"lat": 42.32226, "lon": -83.17631}}, {"facility": "Premier Research", "city": "Trenton", "state": "New Jersey", "zip": "08611", "country": "United States", "geoPoint": {"lat": 40.21705, "lon": -74.74294}}, {"facility": "Manhattan Medical Research", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Holesov", "zip": "76901", "country": "Czechia", "geoPoint": {"lat": 49.33331, "lon": 17.57832}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Krnov", "zip": "79401", "country": "Czechia", "geoPoint": {"lat": 50.08967, "lon": 17.70385}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Pardubice", "zip": "53002", "country": "Czechia", "geoPoint": {"lat": 50.04075, "lon": 15.77659}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Prague", "zip": "14059", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Coatzacoalcos", "zip": "96400", "country": "Mexico", "geoPoint": {"lat": 18.13346, "lon": -94.44242}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Guadalajara", "zip": "44130", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monterrey", "zip": "64620", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Gdansk", "zip": "80-546", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lodz", "zip": "90-242", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lublin", "zip": "20-538", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Poznan", "zip": "61-853", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Szczecin", "zip": "70-506", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Manati Center for Clinical Research Inc", "city": "Manati", "zip": "00674", "country": "Puerto Rico", "geoPoint": {"lat": 18.42745, "lon": -66.49212}}, {"facility": "Consultorio Medico", "city": "San Juan", "zip": "00921", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LY2409021/Placebo", "description": "Period 1: Single daily dose of 20 milligrams (mg) LY2409021 administered orally for 6 weeks; Wash-out: 4 weeks; Period 2: Single daily dose of placebo administered orally for 6 weeks."}, {"id": "FG001", "title": "Placebo/LY2409021", "description": "Period 1: Single daily dose of placebo administered orally for 6 weeks; Wash-out: 4 weeks; Period 2: Single daily dose of 20 milligrams (mg) LY2409021 administered orally for 6 weeks."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "133"}, {"groupId": "FG001", "numSubjects": "137"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "128"}, {"groupId": "FG001", "numSubjects": "133"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Wash-out", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "128"}, {"groupId": "FG001", "numSubjects": "133"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "130"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "130"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "125"}, {"groupId": "FG001", "numSubjects": "128"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LY2409021 20 mg", "description": "Period 1: Single daily dose of 20 mg LY2409021 administered orally for 6 Weeks; Wash-out: 4 weeks; Period 2: Single daily dose of placebo administered orally for 6 weeks."}, {"id": "BG001", "title": "Placebo", "description": "Period 1: Single daily dose of placebo administered orally for 6 weeks; Wash-out: 4 weeks; Period 2: Single daily dose of 20 mg Ly2409021 administered orally for 6 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "133"}, {"groupId": "BG001", "value": "137"}, {"groupId": "BG002", "value": "270"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.3", "spread": "8.9"}, {"groupId": "BG001", "value": "57.2", "spread": "8.9"}, {"groupId": "BG002", "value": "57.7", "spread": "8.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "117"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "153"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "63"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "125"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "130"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "42"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "35"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "179"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "Czechia", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "41"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "146"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}]}, {"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "47"}]}]}]}, {"title": "Diagnosis of Hypertension", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "93"}, {"groupId": "BG002", "value": "182"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "88"}]}]}]}, {"title": "Hemoglobin A1c (HBA1c)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "\u2265 7.5 %", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "100"}]}]}, {"title": "< 7.5%", "categories": [{"measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "170"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure", "description": "Systolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM).", "populationDescription": "Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 6 Weeks", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods"}, {"id": "OG001", "title": "Placebo", "description": "Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.79", "lowerLimit": "1.62", "upperLimit": "3.95"}, {"groupId": "OG001", "value": "0.53", "lowerLimit": "-0.70", "upperLimit": "1.76"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "2.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.11", "ciUpperLimit": "3.40"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Weeks in Mean 24-Hour Diastolic Blood Pressure", "description": "Diastolic blood pressure obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "populationDescription": "Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 6 Weeks", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods"}, {"id": "OG001", "title": "Placebo", "description": "Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.37", "lowerLimit": "0.61", "upperLimit": "2.14"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "-0.76", "upperLimit": "0.77"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.01", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "1.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "2.08"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Peripheral Pulse Rate", "description": "Pulse rate obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "populationDescription": "Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "beats/minute", "timeFrame": "Baseline, 6 Weeks", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods"}, {"id": "OG001", "title": "Placebo", "description": "Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}]}], "classes": [{"title": "24 Hour Pulse Rate", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "lowerLimit": "-0.46", "upperLimit": "1.37"}, {"groupId": "OG001", "value": "0.43", "lowerLimit": "-0.53", "upperLimit": "1.40"}]}]}, {"title": "Mean Daytime Pulse Rate", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.74", "lowerLimit": "-0.26", "upperLimit": "1.75"}, {"groupId": "OG001", "value": "0.56", "lowerLimit": "-0.48", "upperLimit": "1.61"}]}]}, {"title": "Mean Nighttime Pulse Rate", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "lowerLimit": "-1.35", "upperLimit": "0.57"}, {"groupId": "OG001", "value": "-0.04", "lowerLimit": "-1.03", "upperLimit": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Pulse Pressures", "description": "Pulse Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "populationDescription": "Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 6 Weeks", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods."}, {"id": "OG001", "title": "Placebo", "description": "Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}]}], "classes": [{"title": "24-Hour Pulse Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.51", "lowerLimit": "0.76", "upperLimit": "2.25"}, {"groupId": "OG001", "value": "0.62", "lowerLimit": "-0.13", "upperLimit": "1.38"}]}]}, {"title": "Daytime Pulse Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.49", "lowerLimit": "0.68", "upperLimit": "2.29"}, {"groupId": "OG001", "value": "0.54", "lowerLimit": "-0.29", "upperLimit": "1.38"}]}]}, {"title": "Nighttime Pulse Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.51", "lowerLimit": "0.69", "upperLimit": "2.32"}, {"groupId": "OG001", "value": "0.80", "lowerLimit": "0.00", "upperLimit": "1.60"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Mean Arterial Pressures (MAP)", "description": "Mean Arterial Pressures obtained from Ambulatory Blood Pressure Monitoring (ABPM). LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "populationDescription": "Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 6 Weeks", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods"}, {"id": "OG001", "title": "Placebo", "description": "Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}]}], "classes": [{"title": "24 Hour MAP", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.83", "lowerLimit": "0.99", "upperLimit": "2.68"}, {"groupId": "OG001", "value": "0.17", "lowerLimit": "-0.71", "upperLimit": "1.04"}]}]}, {"title": "Daytime MAP", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.04", "lowerLimit": "1.14", "upperLimit": "2.94"}, {"groupId": "OG001", "value": "0.08", "lowerLimit": "-0.86", "upperLimit": "1.03"}]}]}, {"title": "Nighttime MAP", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.31", "lowerLimit": "0.33", "upperLimit": "2.29"}, {"groupId": "OG001", "value": "0.33", "lowerLimit": "-0.68", "upperLimit": "1.33"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Hemoglobin A1c (HbA1c)", "description": "LS Mean of treatment differences, adjusted for country, diagnosis of hypertension, sequence, treatment, period, time within period, treatment by time within period interaction, and the baseline measurement as covariate.", "populationDescription": "Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline, 6 Weeks", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods"}, {"id": "OG001", "title": "Placebo", "description": "Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "239"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.65", "lowerLimit": "-0.72", "upperLimit": "-0.58"}, {"groupId": "OG001", "value": "-0.16", "lowerLimit": "-0.23", "upperLimit": "-0.08"}]}]}]}, {"type": "SECONDARY", "title": "Population Pharmacokinetics: Apparent Clearance of LY2409021", "description": "Population pharmacokinetic parameter apparent clearance (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time and was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.", "populationDescription": "Modified intent-to-treat (mITT) population consisting of all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter per hour (L/hr)", "timeFrame": "Days 7, 21, 42, 70, 77, 91, 112, 140; 15 minute Predose and Days 7 and 77: 1 hour Postdose.", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.406", "spread": "30.7"}]}]}]}, {"type": "SECONDARY", "title": "Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021", "description": "Population pharmacokinetic parameter, apparent volume of distribution (V/F) is a theoretical volume that a drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Apparent volume of distribution (V/F) was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.", "populationDescription": "All randomized participants who received at least 1 one dose of study drug and had at least one measureable drug concentration.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liters", "timeFrame": "Days 7, 21, 42, 70, 77, 91, 112, 140; Predose and Days 7 and 77: 1 hour Postdose.", "groups": [{"id": "OG000", "title": "LY2409021 20 mg", "description": "Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.7", "spread": "23.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "eventGroups": [{"id": "EG000", "title": "LY2409021 20 mg", "description": "AEs (Adverse Event) from Period 1 and 2 combined from LY2409021 20 mg administration", "seriousNumAffected": 4, "seriousNumAtRisk": 258, "otherNumAffected": 49, "otherNumAtRisk": 258}, {"id": "EG001", "title": "Placebo", "description": "AEs from Period 1 and 2 combined from placebo administration.", "seriousNumAffected": 2, "seriousNumAtRisk": 256, "otherNumAffected": 32, "otherNumAtRisk": 256}, {"id": "EG002", "title": "Wash-out", "description": "All AEs included during wash-out period.", "seriousNumAffected": 2, "seriousNumAtRisk": 249, "otherNumAffected": 25, "otherNumAtRisk": 249}, {"id": "EG003", "title": "Follow-up", "description": "All AEs from follow-up period.", "seriousNumAffected": 4, "seriousNumAtRisk": 253, "otherNumAffected": 30, "otherNumAtRisk": 253}], "seriousEvents": [{"term": "Febrile neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Forearm fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Liver function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Pathological fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Plasma cell myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Pulmonary hypertension", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}], "otherEvents": [{"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 253}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 253}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 253}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 12, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 253}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 253}]}, {"term": "Blood pressure diastolic increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 253}]}, {"term": "Heart rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 253}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 5, "numAffected": 3, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 253}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 253}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 5, "numAffected": 3, "numAtRisk": 253}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 258}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 256}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 249}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 253}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "phone": "800-545-5979"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}